Tg Therapeutics, INC 8-K filings

TG Therapeutics reported robust second quarter 2026 results, driven by significant BRIUMVI revenue growth, leading to an upward revision of full-year financial targets.

TG Therapeutics shareholders re-elected all six director nominees but rejected the advisory vote on executive compensation.

TG Therapeutics announced positive Phase 1 data for its subcutaneous BRIUMVI formulation, supporting quarterly dosing and potentially expanding market opportunity for multiple sclerosis treatment.

TG Therapeutics reports positive topline results from its Phase 3 ENHANCE trial, demonstrating bioequivalence for a consolidated single infusion regimen of BRIUMVI in relapsing forms of multiple sclerosis.

TG Therapeutics reported strong first quarter 2026 results, exceeding expectations with significant BRIUMVI revenue and raising full-year financial guidance.

TG Therapeutics, Inc. has amended its financing agreement, securing a new $750 million term loan facility and an uncommitted $250 million additional facility.

TG Therapeutics reported strong fourth quarter and full year 2025 financial results, driven by BRIUMVI sales, and raised its total global revenue guidance for 2026.

TG Therapeutics announced preliminary strong 2025 revenue for BRIUMVI and provided optimistic 2026 financial guidance and key development milestones.

TG Therapeutics announced robust third-quarter 2025 financial results, driven by strong BRIUMVI revenue growth, and raised its full-year revenue guidance.

TG Therapeutics reports robust second quarter 2025 financial results, driven by strong BRIUMVI sales, leading to an upward revision of full-year revenue guidance.

TG Therapeutics, Inc. announced that all proposals, including the re-election of six directors and an amendment to its 2022 Incentive Plan, were approved by stockholders at its 2025 Annual Meeting held on June 12, 2025.

TG Therapeutics announces positive Q1 2025 financial results, driven by strong BRIUMVI sales, and raises its full-year revenue guidance.

TG Therapeutics announces positive Q4 and full year 2024 financial results, driven by strong BRIUMVI sales and provides revenue guidance for 2025.

TG Therapeutics reports strong preliminary revenue for BRIUMVI in 2024 and sets ambitious targets for 2025, including expansion into subcutaneous administration and other autoimmune diseases.

TG Therapeutics reported strong third-quarter 2024 results, driven by robust sales of BRIUMVI, and raised its full-year revenue guidance for the drug.

TG Therapeutics has secured a $250 million loan facility, initiated a $100 million share repurchase program, and reported strong second-quarter sales of Briumvi, leading to increased full-year revenue guidance.

TG Therapeutics stockholders approved amendments to the company's incentive plan and certificate of incorporation at the 2024 annual meeting, increasing authorized shares and removing a limit on full-value awards.

TG Therapeutics reported strong first-quarter sales of Briumvi, exceeding expectations and leading to an increase in full-year revenue guidance.

TG Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting the successful launch of Briumvi and providing a positive outlook for 2024.